Q-omics provides the consensus-scored ZNF71 profile across patient tissues and cancer cell-line models. ZNF71 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, ZNF71 is differentially expressed in 7, with the highest sampling consensus in LIHC. Additionally, ZNF71 RNA expression shows 20,507 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight MESO, LIHC, and ACC as cancer lineages where ZNF71 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF71 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF71 survival associations across molecular data types. ZNF71 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (8) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF71 RNA expression–survival associations across cancer types. High ZNF71 expression shows unfavorable associations in MESO, ACC, LGG and LUSC, but favorable associations in SCLC and THYM. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for ZNF71 RNA expression.
This table summarizes ZNF71 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7, while mass-spec protein shows differences in 1. The strongest signals are observed in LIHC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for ZNF71. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF71 shows lower tumor expression in THCA and higher tumor expression in LIHC, KIRC, CHOL, KIRP and COAD. The LIHC box plot shows higher ZNF71 RNA expression in tumor versus normal tissue (log2 FC = +1.104, t-test p < 0.001).
This table shows molecular features associated with ZNF71 in patient tissues and cancer cell lines. In patient samples, ZNF71 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF71 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BLOOD_Leukemia.
